MedPointe and Opportunities in Specialty Pharma: Speed is Expensive
Executive Summary
The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.You may also be interested in...
MedPointe's Private Dilemma
MedPointe's Private Dilemma
Shire: Too Big For Its Niches
Need a specific report? 1000+ reports available
Buy Reports